Monoclonal Mouse FLNA Antibody
- Known as:
- Monoclonal Mouse FLNA Antibody
- Catalog number:
- abx35000
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- Monoclonal Mouse FLNA Antibody
Related genes to: Monoclonal Mouse FLNA Antibody
- Gene:
- FLNA NIH gene
- Name:
- filamin A
- Previous symbol:
- FLN1, FLN, OPD2, OPD1
- Synonyms:
- ABP-280
- Chromosome:
- Xq28
- Locus Type:
- gene with protein product
- Date approved:
- 1993-03-18
- Date modifiied:
- 2019-04-23
Related products to: Monoclonal Mouse FLNA Antibody
Related articles to: Monoclonal Mouse FLNA Antibody
- Diabetic retinopathy (DR) reflects retinal microvascular injury and systemic immune-metabolic stress, and most public DR transcriptomic datasets lack paired microbiome/metabolomic profiles. We used gutMGene v2.0 as a curated microbe/metabolite-host gene prior and integrated it with peripheral blood transcriptomics from GSE221521. Candidate genes were refined by weighted gene co-expression network analysis (WGCNA), repeated resampling, cross-dataset assessment, mechanism scoring, peripheral blood mononuclear cell (PBMC) single-cell localization and filamin A ()-centered single-cell gene regulatory network (GRN) virtual knockout. The gutMGene prior contained 238 host genes; 15 DR-associated genes overlapped this prior, and WGCNA retained ten candidate gut microbe and microbial metabolite-related genes (GMMRGs): , , , , , , , , and . Resampling prioritized as the most consistent candidate. Cross-dataset assessment localized the strongest signal to type 2 diabetes (T2D) PBMCs, retinal endothelial cells and advanced proliferative diabetic retinopathy with diabetic macular edema (PDR + DME) retinal tissue, with weaker separation in whole blood, broad retinal tissue and six-donor type 1 diabetes (T1D) PBMCs. virtual knockout predicted cell-context-dependent perturbation of immune-related transcriptional programs, including in DR B cells and in DR monocytes/NK cells. This prior-guided study identifies within a ten-gene GMMRG set as a circulating host-response signal that links curated microbe/metabolite-host records to immune-vascular and cytoskeletal remodeling in DR. - Source: PubMed
Publication date: 2026/07/10
Ma ChuanxueWang YujunLiu Yi - Neural stem cells (NSCs) are the basis of neurogenesis and neural regeneration and are widely used as models for drug test and disease therapy. However, how NSCs self-renewal is modulated is not fully understood. In this study, we show that cytoskeletal Filamin A (FLNA) acts as a negative regulator in NSCs proliferation or self-renew. FLNA can be localized to the nucleoli of both NE-4C and C17.2 cell lines. FLNA silencing activated the expression of Pol Ⅰ products. In contrast, FLNA overexpression dampened rDNA transcription, suggesting that FLNA suppresses NSCs proliferation by downregulating Pol Ⅰ-directed transcription. Mechanistically, FLNA downregulates Pol I-directed transcription by inhibiting RRN3 expression and the occupancies of the Pol I transcription machinery factors at the rDNA promoter. In addition, FLNA suppresses NSCs proliferation by maintaining high levels of P53 and PTEN expression. Finally, we show that FLNA silencing does not affect the identity of neural stem cells, but inhibits neuronal differentiation from neural stem cells. These findings provide a novel insight into the mechanisms by which FLNA negatively regulates NSCs self-renew. - Source: PubMed
Publication date: 2026/07/21
Wu ZihuiZhou XiangyuSong XiaoyeWang YeYu DeenZhao ShashaDeng Wensheng - Multiple myeloma (MM) remains an incurable hematological malignancy with heterogeneous outcomes, necessitating the identification of novel prognostic markers for improved patient stratification and treatment. - Source: PubMed
Publication date: 2026/07/16
Xu YuxiuSun XiaoliYang JingMa DongshengWan JiangweiLei TingtingWang Tao - Bladder cancer (BLCA) remains a formidable clinical challenge due to its high recurrence rate and complex molecular landscape. The integrated roles of liquid-liquid phase separation (LLPS), epithelial-mesenchymal transition (EMT), and ferroptosis in BLCA progression remain largely unresolved. - Source: PubMed
Publication date: 2026/06/24
Zhang XimoGe PengChen QiweiWang ShujingYang Deyong - ObjectiveDisulfidptosis, a newly discovered mechanism of cell death, may play a significant role in cancer initiation, progression, and prognosis. However, studies on the prognostic role of Disulfidptosis-Related Genes (DRGs) across cancers remain limited. This study aims to systematically explore the prognostic value of DRGs in various cancer types by constructing a prognosis model based on DRGs and analyzing their associations with tumor biological characteristics.MethodsThis was a pan-cancer bioinformatics study combined with in vitro qRT-PCR validation. Public transcriptomic and clinical data from cancer patients were obtained from The Cancer Genome Atlas (TCGA). Samples were randomly divided into training and validation cohorts at a 1:1 ratio. In the training cohort, least absolute shrinkage and selection operator (LASSO) regression was used to identify prognosis-related DRGs, followed by multivariate Cox regression to construct a DRG-based risk score. The prognostic value of the risk score was evaluated using Cox regression, Kaplan-Meier survival analysis, and nomogram construction. Gene set activity analysis was performed to assess the associations between the DRG score and tumor-related biological processes, including angiogenesis, epithelial-mesenchymal transition (EMT), and cell cycle activity. To further validate the expression patterns of key DRGs in osteosarcoma, osteosarcoma-related transcriptomic data from TARGET and normal tissue data from GTEx were analyzed. The 16 selected DRGs were intersected with osteosarcoma-related differentially expressed genes, and 10 overlapping genes were further validated by qRT-PCR in osteosarcoma cell lines and normal osteoblasts.ResultsKey DRGs identified via LASSO regression showed significant prognostic value in pan-cancer analysis. The resulting risk model effectively stratified patients by survival outcomes and performed well in both training and validation cohorts, indicating strong clinical potential. SsGSEA revealed associations between DRG risk scores and malignant tumor features such as angiogenesis, EMT, and cell cycle dysregulation. Differential expression and GO enrichment analyses indicated that related genes were involved in metabolism, apoptosis, and immune processes. qRT-PCR validation in normal osteoblasts (hFOB) and seven osteosarcoma cell lines showed that NDUFA11 and NDUFS1 were generally downregulated, whereas ACTB, WASF2, FLNA, PRC1, ACTN4, PGD, RAC1, and FLNB were generally upregulated in most osteosarcoma cell lines compared with hFOB cells. These expression patterns were broadly consistent with the bioinformatics results and support the potential relevance of these genes in osteosarcoma progression.ConclusionBy constructing a prognostic model based on DRGs, this study reveals the significant prognostic value of DRGs across pan-cancers and further validates their association with tumor malignant characteristics. The results suggest that DRG score can serve as an effective prognostic indicator for cancer patient survival and have specific implications in osteosarcoma. In the future, DRG-based scoring systems may serve as novel biomarkers and therapeutic targets. - Source: PubMed
Publication date: 2026/06/29
Wang JinqiuHuang HuiLiu Dehuai